Revision of Full-Year Earnings Forecast(As of October, 31)

We have decided to revise the consolidated earnings forecast for the fiscal year ending March 31, 2024, based on these actual results, as follows.

 

(Reason for Adjustment)

Consolidated net sales and each profit for the first half of the fiscal year ending March 31, 2024 exceeded the previously announced forecasts due to favorable increase in the number of prescriptions in the dispensing pharmacy business, steady sales of existing products and new NHI-listed products in the pharmaceutical manufacturing and sales business, and an increase in staffing demand for pharmacists in the Medical Professional Staffing and Placement Business as well as the contribution of company-wide cost containment to business results.


For the full-year forecast for the fiscal year ending March 31, 2024, based on the results of the first half of the current fiscal year, we expect consolidated net sales and each profit to exceed the previous forecast as well, mainly due to the expected contribution from continued company-wide cost containment in the third quarter and beyond.

 

(百万円) 
FY2023
Results
FY2024
Previous
Forecasts
FY2024
Revised
Forecasts
YoY
Change
Net sales 313,318 334,400 337,100 7.6%
Operating profit 7,586 6,400 8,400 10.7%
Ordinary profit 7,682 6,300 8,300 8.0%
Profit attributable to
owners of parent
4,458 3,200 4,300 △3.6%